1999 Fiscal Year Final Research Report Summary
A STUDY ON THE MEDICAL CARE COST FOR PEOPLE WITH HIV / AIDS IN JAPAN
| Project/Area Number |
09670427
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Public health/Health science
|
|---|
| Research Institution | KANAGAWA PREFECTURAL COLLEGE OF NURSING AND MEDICAL TECHNOLOGY |
|---|
Principal Investigator |
ICHIKAWA Seiichi LABORATORY OF PUBLIC HEALTH, KANAGAWA PREFECTURAL COLLEGE OF NURSING AND MEDICAL TECHNOLOGY, PROFESSOR, 衛生技術科, 教授 (90106302)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
大屋 日登美 神奈川県立衛生短期大学, 衛生技術科, 助手 (80249060)
|
|---|
| Project Period (FY) |
1997 – 1999
|
| Keywords | HIV / AIDS / anti-HIV / drugs / The cost of medicating HIV / AIDS |
|---|
| Research Abstract |
Objective : In this study, we categorized patients with HIV (PWH) and AIDS (PWA) according to the CD4 cell count, and separately analyzed the costs of outpatient and inpatient care for the hemophiliac and non-hemophiliac patients in each category.
Materials ＆ Methods : HIV infection was classified into 4 stages reflecting severity of disease. The stages were AC-1 (n=28), CD4 cell count ≧ 500 ; AC-2 (n=45), CD4 count 200-500 ; AC-3 (n=34), CD4 count less than 200 ; and AIDS patients (n=46). The costs of outpatient and inpatient care for PWH and PWA were investigated on the basis of receipts for monthly statements of insurance payments. The costs of medication were calculated item by item for each patient, and the mean cost of medical care par day was calculated for the 4 disease stage groups by dividing the costs by the actual number of days of outpatient or inpatient care. In the patients receiving anit-HIV drugs, we calculated the costs of AZT and ddI, and determined the percentage of the total cost of medical care occupied by anti-HIV drugs.
Results : The monthly cost of medical care for the non-hemophiliac patients receiving anti-HIV drugs was 2.5 times and 3.5 times higher in the AC-2 and AC-3 groups, respectively, than that in the AC-1 group of patients not receiving anti-HIV drugs.
The cost of anti-HIV drugs accounted for more than 60% of the total cost. A similar tendency was also observed in the hemophiliac patients, and anti-HIV drugs accounted for 40%-60% of the cost of medical care excluding the home-care costs of coagulation factor products. The life-time cost for HIV / AIDS treatment with anti-HIV drugs was estimated to be 13,440,000 yen.
Conclusion : The cost of outpatient care increased a the disease progressed ; especially, in Terms of the use of anti-HIV drugs.
|
Research Products
(2 results)
